Vijay-Robinson Sequential Suture Holder: Patent Approved U.S 8,480,690.
Designed by Dr. Vijay and his team, the patent approved Vijay-Robinson Sequential Suture Holder is an innovative medical device used in open-heart surgery and surgeries involving multiple sequential sutures. The product is designed to be easily affixed to a surgical drape and as the sutures are passed through the annulus of the heart valve, they are applied to clamps and placed into the instrument. Throughout the procedure, these sutures are removed one by one, in a sequential fashion and applied to the sewing ring of the artificial heart valve. The needles will then be cut and all the sequential sutures in the instrument are lifted up to manipulate the valve into the proper position. Subsequently, without any strings hanging underneath, the sutures are tied and cut. The instrument can also be used in any surgery where numerous sutures are required and needed to be kept in order.
LRMT is in corroboration with Jim Hughes, a design engineer, and David Bailey, a consulting engineer, who have lead to the creation of the prototype instrument and blueprints. The instrument has been demonstrated in open-heart surgery at Tampa General Hospital.
Vijay Tri-leaflet Self Retaining Retractor -US PATENT APPROVED
The purpose of the instrument is to improve visualization for aortic and pulmonary valve surgery. The currently available instrument is a spoon-like retractor, which is held by a surgery assistant and retracts the aortic or pulmonary artery walls. This instrument provides some exposure, however, based on years of experience, Dr. Vijay notes that it is a struggle for the assistant to hold the retractor in place and maintain proper concentration. Presently, there is no self-retaining retractor of which will retract the aortic or pulmonary wall for proper exposure for the surgical procedure.Dr. Vijay design an instrument that can be fixed to the sternal retractor, which should be adjustable and movable.
Regen Eye Drops – Patent Pending
The Regen Eye Drops are used for the treatment of the dry-eye syndrome. It is estimated that 30 million US patients suffer from dry-eye syndrome without a cure. Current products available provide only mild to moderate relief from symptoms.
Dry eye is a condition in which there are insufficient tears to lubricate and nourish the eye. Tears are necessary for maintaining the health of the front surface of the eye and for providing clear vision. People with dry eyes either do not produce enough tears or have a poor quality of tears. Dry eye is a common and often chronic problem, particularly in older adults. With each blink of the eyelids, tears are spread across the front surface, known as the cornea. Tears provide lubrication, reduce the risk of eye infection, wash away foreign matter in the eye and keep the surface of the eye smooth and clear. Excess tears in the eyes flow into small drainage ducts, in the inner corners of the eyelids, which drain in the back of the nose. Dry eyes result from an improper balance of tear production and drainage. LRMT is in the development stage of a proprietary compound, which may be the most effective in the treatment of dry eye syndrome.
Presently, LRMT has completed laboratory experiments with its proprietary compound on 120 male adult Lewis rats. The study was completed according to a protocol approved by the IACUC committee at the University of Central Florida. We are currently working to obtain licensing and to respectively receive royalties from pharmaceutical companies.
Brain Cooling-Investigational Stage
The Therapeutic Hypothermia and Cardio-Respiratory Augmentation Apparatus is a device that is meant to preserve the brain function during complex medical surgeries. Designed by Dr. Vijay, this innovative concept combines Enhanced Extracorporeal Counter Pulsation (EECP) along with Therapeutic Hypothermia (TH). This new idea and invention combine TH for neuro cardioprotection with cardio-respiratory augmentation, which can be a new approach in many clinical fields, particularly in out-of-hospital as well as in-hospital for cardiac arrest patients who have been successfully resuscitated.
The current techniques available to achieve rapid TH have not been satisfactory and most of the procedures are invasive which requires hospitalization including intensive care admission. The ideal way of effectively achieving TH is achievable by means of non-invasive techniques. The table below highlights some of the TH cooling techniques:
The LRMT's brain cooling product of combining ECCP along with TH for neuro cardiac protection with cardio-respiratory augmentation has many benefits as described as follows:
LRMT has completed a feasibility study with a Boston company to establish system functionality. Two of the components of the Brain Cooling System are already on the market and have already been approved by the FDA. LRMTwill continue these investigation studies. The estimated cost per system is estimated at $100,000 with an estimated retail cost of $150,000 per unit. LRMT is seeking to license or suitable partnership.